Loading stock data…
CPRX
$28.74+0.61 (+2.17%)
Market ClosedLast close May 1
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Catalyst Pharmaceuticals, Inc. in the Healthcare sector is trading at $28.74. The stock is currently 12% below its 52-week high of $32.56, remaining 26.6% above its 200-day moving average. Technical signals show neutral RSI of 70 and bullish MACD crossover, explaining why CPRX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.74
Potential Upside
25.7%
Whystock Fair Value$36.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambe...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.44
Beta
Defensive asset. Lower volatility than the S&P 500.
0.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.01%
Volume
Today's trading volume
1.36M
Recent News
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum
What Catalyst Pharmaceuticals stock’s recent move may mean for investors Catalyst Pharmaceuticals (CPRX) has drawn closer attention after a recent share price move, prompting investors to look more closely at how its current valuation lines up with the company’s rare disease focused business profile. See our latest analysis for Catalyst Pharmaceuticals. At a share price of $28.26, Catalyst Pharmaceuticals has seen stronger recent momentum, with a 7 day share price return of 8.94% and a 30 day...
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.